Is there a correlation with severity of rash as an adverse event and response rate with capivasertib?

While it is tempting to hope that patients with significant side effects on targeted therapies might be more likely to demonstrate an antitumor response to that treatment, and there is limited data to suggest a possible correlation between immune-related adverse events and response to immunotherapy,...

I am not aware about correlation between severity of rash and response to capivasertib.